RCEL · AVITA Medical, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Based on the Company's liquidity position and the Company's current forecast of operating results and cash flows, management determined there is substantial doubt about the Company's ability to continue as a going concern over the next twelve months following the date of issuance of these Consolidated Financial Statements due to the Company's debt repayment obligations, recurring losses, and historical negative cash flows.”View the 10-Q filed Aug 6, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jun 30, 2020; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Cash, cash equivalents, and marketable securities | $11.1M | Q2 2026 | — |
| Cohealyx revenue | $1.7M | Q2 2026 | — |
| International revenue | $0.9M | Q2 2026 | — |
| Net cash use | $3.2M | Q2 2026 | — |
| PermeaDerm revenue | $0.6M | Q2 2026 | — |
| RECELL revenue | $18.5M | Q2 2026 | — |
| RECELL-only gross margin | 86% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
RCEL
this stock
AVITA Medical, Inc.
|
$288.39M | +199.7% | +11.5% | — | 8.4% |
|
ABT
Abbott Laboratories
|
$196.27B | -8.7% | +5.7% | 31.6 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -3.3% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -2.0% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -45.5% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jun 30, 2020; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| RCEL | +27.3% | +109.3% | +102.4% | +135.0% | +199.7% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +27.8% | +106.4% | +90.8% | +132.1% | +186.9% |